Hirata Y
2nd Department of Internal Medicine, Tokyo Medical and Dental University.
Nihon Rinsho. 1993 Jun;51(6):1540-7.
Since the discovery of a potent endothelium-derived vasoconstrictor peptide, termed endothelin (ET) in 1988, recent studies using molecular biology technique have revealed the existence of ET isopeptides (ET-1, ET-2, ET-3) and receptor subtypes (ETA, ETB). In cardiovascular system, ET family plays important roles not only in regulation of vascular tonus as a vasoconstrictor, but also in cardiovascular remodeling as a growth factor. Development and application of antagonists selective for ETA and ETB receptor and inhibitor of ET-converting enzyme should elucidate pathophysiological roles of ET family and its receptors in cardiovascular diseases.
自1988年发现一种强效的内皮源性血管收缩肽，即内皮素（ET）以来，最近使用分子生物学技术的研究揭示了ET同工肽（ET-1、ET-2、ET-3）和受体亚型（ETA、ETB）的存在。在心血管系统中，ET家族不仅作为血管收缩剂在调节血管张力方面发挥重要作用，而且作为生长因子在心血管重塑中也发挥重要作用。选择性作用于ETA和ETB受体的拮抗剂以及ET转换酶抑制剂的开发和应用，应能阐明ET家族及其受体在心血管疾病中的病理生理作用。
